Microbot Medical Receives Israeli Approval for Liberty System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Microbot Medical announced that it has achieved a significant regulatory milestone as Israel becomes the second jurisdiction - and the first outside of the U.S. - to grant marketing clearance for the Liberty System. The regulatory approval from the Israeli Ministry of Health's AMAR Division, the authority responsible for medical device regulation in Israel, allows the Company to market and commercialize the Liberty System in Israel, which also enables the Company to obtain a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions. The Company continues to pursue CE Mark certification and is working toward completion by the end of 2026, in preparation for the next phase of commercial expansion into the EU market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBOT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBOT
Wall Street analysts forecast MBOT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.930
Low
5.50
Averages
8.75
High
12.00
Current: 1.930
Low
5.50
Averages
8.75
High
12.00
About MBOT
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Israel Approves LIBERTY System for Marketing
- Regulatory Milestone: Israel becomes the second jurisdiction to approve the LIBERTY System after the U.S., with the marketing clearance granted by the Israeli Ministry of Health's AMAR Division marking a significant advancement in the company's international market expansion, expected to drive future commercial activities.
- Market Expansion Support: This approval enables Microbot Medical to obtain a Free Sale Certificate, thereby supporting submissions and commercial activities in additional jurisdictions, enhancing its competitiveness in the global market.
- CE Mark Certification Process: The company is actively pursuing CE Mark certification, aiming for completion by the end of 2026, which will lay the groundwork for the next phase of commercial expansion into the EU market, demonstrating its commitment to international markets.
- Success in U.S. Market: The successful launch of the LIBERTY System in the U.S. has already led to adoption by multiple hospitals in states like Georgia, Florida, and New York, indicating strong recognition and demand for the system in the healthcare industry, further propelling the implementation of the company's growth strategies.
See More
Microbot Medical to Host Analyst Conference Call on LIBERTY System
- Conference Call Scheduled: Microbot Medical will host an analyst and investor conference call on May 18, 2026, at 3:00 PM ET to review the progress of the LIBERTY® Endovascular Robotic System's market release, ensuring investors receive accurate information and correcting misleading statements from a recent third-party article.
- Expert Participation: The call will be led by Chairman and CEO Harel Gadot, with vascular surgeon Dr. Charles Briggs sharing his experiences using the LIBERTY System, highlighting its practical applications and significance in clinical settings.
- Transparency in Information: Microbot Medical plans to review claims made in the third-party article to correct misunderstandings about its products and technology, ensuring investors are fully informed of the company's actual situation, thereby enhancing market confidence.
- Technological Innovation: The LIBERTY System, as the first single-use, remotely operated robotic solution, aims to improve precision and safety in endovascular procedures, with Microbot Medical driving the future of endovascular care through ongoing technological advancements.
See More
Microbot Medical Reports Q1 Loss, Shares Drop 17%
- Disappointing Earnings: Microbot Medical (MBOT) reported a Q1 loss of $0.05, an improvement from a loss of $0.08 a year earlier, yet still falling short of market expectations, resulting in a 17% drop in share price.
- Market Release Progress: The company initiated the full market release of the LIBERTY system in Q2, with revenue halfway through Q2 already exceeding total Q1 revenue, indicating improved market acceptance of the product.
- Short Report Impact: White Diamond Research disclosed its short position in Microbot (MBOT), exacerbating negative market sentiment and leading to a decline in investor confidence.
- Short Interest Situation: Microbot has a short interest of 12.8%, reflecting market concerns about its future performance, which could impact its financing capabilities and stock price stability.
See More
Microbot Medical Reports Significant Revenue Growth in Q2
- Market Release Impact: Microbot Medical's revenue for Q2 2026 has already surpassed Q1, driven by the Full Market Release of the LIBERTY System, indicating accelerated utilization and adoption across multiple sales territories.
- Increase in Customer Orders: The company reports a significant rise in recurring customer orders and new accounts, with a growing pipeline of potential future accounts, reflecting sustained market demand for the LIBERTY System.
- Diverse Procedures: The LIBERTY System has been adopted in hospitals across six states, performing complex surgeries including the world's first robotic Prostatic Artery Embolization, further validating its value and application potential in the medical field.
- Enhanced Industry Support: With updated guidelines on occupational radiation and musculoskeletal protection adopted by at least nine medical societies, commercial adoption of the LIBERTY System is expected to accelerate, bolstered by the upcoming Global Embolization Symposium, facilitating the company's market growth.
See More
Microbot Medical Expands into International Markets
- International Market Launch: Microbot Medical has successfully completed its Limited Market Release, followed by a Full Market Release in the U.S., demonstrating strong physician interest and indicating robust commercial readiness in densely populated regions.
- Sales Strategy Appointment: The company appointed Alon Tamir as Vice President of Sales for Europe, the Middle East, and Asia (EMEA), aiming to leverage the successful commercial launch of the LIBERTY system to drive expansion into international markets, which is expected to significantly enhance market share.
- Market Opportunity Analysis: The EMEA region's peripheral endovascular procedure volume is comparable to that of the U.S., at approximately 2.3 million procedures, highlighting Microbot's expansion potential, especially with anticipated CE mark approval accelerating international market entry.
- Regulatory and Commercial Capability Building: The company will continue to prioritize the U.S. market while establishing the regulatory, operational, and commercial core capabilities necessary for entering international markets, ensuring successful commercialization globally.
See More
LIBERTY System Gains Support from Medical Societies
- Support from Medical Societies: The Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) have jointly released updated guidelines emphasizing the reduction of radiation exposure and improvement of working conditions for healthcare providers, indicating strong endorsement for the LIBERTY System, which may enhance its market acceptance.
- Health Risk Awareness: The new guidelines highlight significant long-term health risks associated with prolonged radiation exposure, particularly affecting female practitioners, and the LIBERTY System's design aims to mitigate these risks, potentially attracting more professionals into the field.
- Remote Operation Benefits: The LIBERTY System's remote operation capabilities allow physicians to work away from radiation sources while seated, reducing musculoskeletal strain and improving workflow efficiency, which could enhance the overall operational dynamics in interventional care.
- Policy Advocacy: The American Medical Association (AMA) adopted a new policy in late 2025 emphasizing protections for healthcare professionals, further driving demand for the LIBERTY System and reflecting a growing industry focus on occupational safety.
See More
Israel Approves LIBERTY System for Marketing
- Regulatory Milestone: Israel becomes the second jurisdiction to approve the LIBERTY System after the U.S., with the marketing clearance granted by the Israeli Ministry of Health's AMAR Division marking a significant advancement in the company's international market expansion, expected to drive future commercial activities.
- Market Expansion Support: This approval enables Microbot Medical to obtain a Free Sale Certificate, thereby supporting submissions and commercial activities in additional jurisdictions, enhancing its competitiveness in the global market.
- CE Mark Certification Process: The company is actively pursuing CE Mark certification, aiming for completion by the end of 2026, which will lay the groundwork for the next phase of commercial expansion into the EU market, demonstrating its commitment to international markets.
- Success in U.S. Market: The successful launch of the LIBERTY System in the U.S. has already led to adoption by multiple hospitals in states like Georgia, Florida, and New York, indicating strong recognition and demand for the system in the healthcare industry, further propelling the implementation of the company's growth strategies.
See More
Microbot Medical to Host Analyst Conference Call on LIBERTY System
- Conference Call Scheduled: Microbot Medical will host an analyst and investor conference call on May 18, 2026, at 3:00 PM ET to review the progress of the LIBERTY® Endovascular Robotic System's market release, ensuring investors receive accurate information and correcting misleading statements from a recent third-party article.
- Expert Participation: The call will be led by Chairman and CEO Harel Gadot, with vascular surgeon Dr. Charles Briggs sharing his experiences using the LIBERTY System, highlighting its practical applications and significance in clinical settings.
- Transparency in Information: Microbot Medical plans to review claims made in the third-party article to correct misunderstandings about its products and technology, ensuring investors are fully informed of the company's actual situation, thereby enhancing market confidence.
- Technological Innovation: The LIBERTY System, as the first single-use, remotely operated robotic solution, aims to improve precision and safety in endovascular procedures, with Microbot Medical driving the future of endovascular care through ongoing technological advancements.
See More
Microbot Medical Reports Q1 Loss, Shares Drop 17%
- Disappointing Earnings: Microbot Medical (MBOT) reported a Q1 loss of $0.05, an improvement from a loss of $0.08 a year earlier, yet still falling short of market expectations, resulting in a 17% drop in share price.
- Market Release Progress: The company initiated the full market release of the LIBERTY system in Q2, with revenue halfway through Q2 already exceeding total Q1 revenue, indicating improved market acceptance of the product.
- Short Report Impact: White Diamond Research disclosed its short position in Microbot (MBOT), exacerbating negative market sentiment and leading to a decline in investor confidence.
- Short Interest Situation: Microbot has a short interest of 12.8%, reflecting market concerns about its future performance, which could impact its financing capabilities and stock price stability.
See More
Microbot Medical Reports Significant Revenue Growth in Q2
- Market Release Impact: Microbot Medical's revenue for Q2 2026 has already surpassed Q1, driven by the Full Market Release of the LIBERTY System, indicating accelerated utilization and adoption across multiple sales territories.
- Increase in Customer Orders: The company reports a significant rise in recurring customer orders and new accounts, with a growing pipeline of potential future accounts, reflecting sustained market demand for the LIBERTY System.
- Diverse Procedures: The LIBERTY System has been adopted in hospitals across six states, performing complex surgeries including the world's first robotic Prostatic Artery Embolization, further validating its value and application potential in the medical field.
- Enhanced Industry Support: With updated guidelines on occupational radiation and musculoskeletal protection adopted by at least nine medical societies, commercial adoption of the LIBERTY System is expected to accelerate, bolstered by the upcoming Global Embolization Symposium, facilitating the company's market growth.
See More
Microbot Medical Expands into International Markets
- International Market Launch: Microbot Medical has successfully completed its Limited Market Release, followed by a Full Market Release in the U.S., demonstrating strong physician interest and indicating robust commercial readiness in densely populated regions.
- Sales Strategy Appointment: The company appointed Alon Tamir as Vice President of Sales for Europe, the Middle East, and Asia (EMEA), aiming to leverage the successful commercial launch of the LIBERTY system to drive expansion into international markets, which is expected to significantly enhance market share.
- Market Opportunity Analysis: The EMEA region's peripheral endovascular procedure volume is comparable to that of the U.S., at approximately 2.3 million procedures, highlighting Microbot's expansion potential, especially with anticipated CE mark approval accelerating international market entry.
- Regulatory and Commercial Capability Building: The company will continue to prioritize the U.S. market while establishing the regulatory, operational, and commercial core capabilities necessary for entering international markets, ensuring successful commercialization globally.
See More
LIBERTY System Gains Support from Medical Societies
- Support from Medical Societies: The Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) have jointly released updated guidelines emphasizing the reduction of radiation exposure and improvement of working conditions for healthcare providers, indicating strong endorsement for the LIBERTY System, which may enhance its market acceptance.
- Health Risk Awareness: The new guidelines highlight significant long-term health risks associated with prolonged radiation exposure, particularly affecting female practitioners, and the LIBERTY System's design aims to mitigate these risks, potentially attracting more professionals into the field.
- Remote Operation Benefits: The LIBERTY System's remote operation capabilities allow physicians to work away from radiation sources while seated, reducing musculoskeletal strain and improving workflow efficiency, which could enhance the overall operational dynamics in interventional care.
- Policy Advocacy: The American Medical Association (AMA) adopted a new policy in late 2025 emphasizing protections for healthcare professionals, further driving demand for the LIBERTY System and reflecting a growing industry focus on occupational safety.
See More
